Email: a.rothman@sheffield.ac.uk

Research profile and key clinical specialties

Our group focuses on the development of novel therapeutic strategies for the treatment of cardiovascular disease and pulmonary hypertension.

Following successful first-in-human and phase I/II studies, recent projects have developed products that are now have regulatory approval and provide reimbursement.

Current studies focus on the use of novel technologies to improve clinical study methodology and clinical practise.

I work clinically as part of the interventional cardiologist and pulmonary hypertension teams in Sheffield.

Two key publications

• Rothman A.M.K. et, al. (2016). MicroRNA-140-5p and SMURF1 Regulate Pulmonary Arterial Hypertension. J. Clin Invest. 2016;126(7):2495-2508. doi:10.1172/JCI83361, PMID: 27214554
• Mullins, W., Sharif, F., DuPont, M., Rothman, A.M.K., Wijns, W. (2020) Digital Health Care Solution for Proactive Heart Failure Management: Results of the SIRONA First-in-Human Study. European Journal of Heart Failure. doi.org/10.1002/ejhf.1870

Possible PhD projects

• Remote monitoring in patients with pulmonary arterial hypertension.
• The effect of SMURF1 inhibition in patients with pulmonary arterial hypertension.

More information

In Sheffield our team is funded with awards from the Wellcome Trust, MRC and BHF.

Keywords: Cardiovascular, cardiologist pulmonary, hypertension, SMURF1, Alex, Rothman, Sheffield

Related